Overview of mimotopes and related strategies in tumor vaccine development

References

• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Dalgleish A. Overcoming technical challenges in the development of cancer vaccines. IDrugs10(7), 463–467 (2007).
   PubMed Web of Science ®Google Scholar
• Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol.21(12), 2415–2432 (2003).
   PubMed Web of Science ®Google Scholar
• Copier J, Ward S, Dalgleish A. Cell based cancer vaccines: regulatory and commercial development. Vaccine25(Suppl. 2), B35–B46 (2007).
   PubMed Web of Science ®Google Scholar
• Ward S, Copier J, Dalgleish A. Technical challenges facing therapeutic cancer vaccines. Curr. Opin. Drug Discov. Dev.11(2), 168–177 (2008).
   PubMedGoogle Scholar
• Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. Vaccine25(16), 3032–3037 (2007).
   PubMed Web of Science ®Google Scholar
• Monzavi-Karbassi B, Pashov A, Jousheghany F, Artaud C, Kieber-Emmons T. Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. Int. J. Mol. Med.17(6), 1045–1052 (2006).
   PubMed Web of Science ®Google Scholar
• Hafner C, Wagner S, Jasinska J et al. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J. Invest. Dermatol.124(1), 125–131 (2005).
   PubMed Web of Science ®Google Scholar
• Sette A, Livingston B, McKinney D et al. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals29(3–4), 271–276 (2001).
   PubMed Web of Science ®Google Scholar
• Fan D, Zhang X, Chen X et al. Bird’s-eye view on gastric cancer research of the past 25 years. J. Gastroenterol. Hepatol.20(3), 360–365 (2005).
   PubMed Web of Science ®Google Scholar
• Felici F, Luzzago A, Folgori A, Cortese R. Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. Gene128(1), 21–27 (1993).
   PubMed Web of Science ®Google Scholar
• Scholl I, Wiedermann U, Forster-Waldl E et al. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clin. Exp. Allergy32(11), 1583–1588 (2002).
   PubMedGoogle Scholar
• Sidhu SS, Lowman HB, Cunningham BC, Wells JA. Phage display for selection of novel binding peptides. Methods Enzymol.328, 333–363 (2000).
   PubMed Web of Science ®Google Scholar
• Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science249(4967), 386–390 (1990).
   PubMed Web of Science ®Google Scholar
• Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene73(2), 305–318 (1988).
   PubMed Web of Science ®Google Scholar
• Partidos CD. Peptide mimotopes as candidate vaccines. Curr. Opin. Mol. Ther.2(1), 74–79 (2000).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Klinger M, Wagner S et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J. Immunol.173(1), 394–401 (2004).
   PubMed Web of Science ®Google Scholar
• Irving MB, Pan O, Scott JK. Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr. Opin. Chem. Biol.5(3), 314–324 (2001).
   PubMed Web of Science ®Google Scholar
• Sherev T, Wiesmuller KH, Walden P. Mimotopes of tumor-associated T-cell epitopes for cancer vaccines determined with combinatorial peptide libraries. Mol. Biotechnol.25(1), 53–61 (2003).
   PubMed Web of Science ®Google Scholar
• Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr. Opin. Immunol.7(3), 349–354 (1995).
   PubMed Web of Science ®Google Scholar
• Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol.491, 369–402 (2001).
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Tainsky MA. Non-traditional immunogens and their application to immunotherapy. Curr. Opin. Mol. Ther.10(1), 62–67 (2008).
   PubMedGoogle Scholar
• Grothaus MC, Srivastava N, Smithson SL et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine18(13), 1253–1263 (2000).
   PubMed Web of Science ®Google Scholar
• Gundlach BR, Wiesmuller KH, Junt T, Kienle S, Jung G, Walden P. Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL. J. Immunol.156(10), 3645–3651 (1996).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Jensen-Jarolim E. Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunology Lett.113(1), 1–5 (2007).
   PubMed Web of Science ®Google Scholar
• de Cerio AL, Zabalegui N, Rodriguez-Calvillo M, Inoges S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene26(25), 3594–3602 (2007).
   PubMed Web of Science ®Google Scholar
• Alfonso M, Diaz A, Hernandez AM et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol.168(5), 2523–2529 (2002).
   PubMed Web of Science ®Google Scholar
• Mittelman A, Chen ZJ, Kageshita T et al. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J. Clin. Invest.86(6), 2136–2144 (1990).
   PubMed Web of Science ®Google Scholar
• Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2–23. Cancer Res.54(2), 415–421 (1994).
   PubMed Web of Science ®Google Scholar
• Mittelman A, Wang X, Matsumoto K, Ferrone S. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2–23. Hybridoma14(2), 175–181 (1995).
   PubMedGoogle Scholar
• Forster-Waldl E, Riemer AB, Dehof AK et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol. Immunol.42(3), 319–325 (2005).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Forster-Waldl E, Bramswig KH et al. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur. J. Immunol.36(5), 1267–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Fest S, Huebener N, Weixler S et al. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res.66(21), 10567–10575 (2006).
   PubMed Web of Science ®Google Scholar
• Bolesta E, Kowalczyk A, Wierzbicki A et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res.65(8), 3410–3418 (2005).
   PubMed Web of Science ®Google Scholar
• Kowalczyk A, Wierzbicki A, Gil M et al. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol. Immunother.56(9), 1443–1458 (2007).
   PubMed Web of Science ®Google Scholar
• Wondimu A, Zhang T, Kieber-Emmons T et al. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol. Immunother.57(7), 1079–1089 (2008).
   PubMed Web of Science ®Google Scholar
• Hardy B, Indjiia L, Rodionov G, Raiter A, Inbal A. Treatment with monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma. Int. J. Oncol.19(5), 897–902 (2001).
   PubMed Web of Science ®Google Scholar
• Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc.Natl Acad. Sci.USA94(11), 5756–5760 (1997).
   PubMed Web of Science ®Google Scholar
• Hardy B, Yampolski I, Kovjazin R, Galli M, Novogrodsky A. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. Cancer Res.54(22), 5793–5796 (1994).
   PubMed Web of Science ®Google Scholar
• Hardy B, Raiter A. A mimotope peptide-based anti-cancer vaccine selected by monoclonal antibody. Vaccine23(34), 4283–4291 (2005).
   PubMed Web of Science ®Google Scholar
• Feinmesser M, Raiter A, Hardy B. Prevention of melanoma metastases in lungs of treated and peptide immunized mice. Int. J. Oncol.29(4), 911–917 (2006).
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol.2(2), 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J. Natl Cancer Inst.97(22), 1663–1670 (2005).
   PubMed Web of Science ®Google Scholar
• Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta1198(2–3), 165–184 (1994).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Untersmayr E, Knittelfelder R et al. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res.67(7), 3406–3411 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang B, Liu W, Qu H et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. J. Biol. Chem.280(6), 4656–4662 (2005).
   PubMed Web of Science ®Google Scholar
• Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J. Lab. Clin. Med.134(5), 445–450 (1999).
   PubMed Web of Science ®Google Scholar
• Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood108(6), 1975–1978 (2006).
   PubMed Web of Science ®Google Scholar
• Li M, Yan Z, Han W, Zhang Y. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies. Cell. Immunol.239(2), 136–143 (2006).
   PubMed Web of Science ®Google Scholar
• Li M, Han W, Zhang Q, Xue X, Wang Z, Zhang Y. Development of a mimotope-based vaccine against CD20 antigen. Protein Pept. Lett.14(6), 610–614 (2007).
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Caragnano MA, Dammacco F. CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases. Ann. NY Acad. Sci.1051, 672–683 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner S, Hafner C, Allwardt D et al. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J. Immunol.174(2), 976–982 (2005).
   PubMed Web of Science ®Google Scholar
• Hafner C, Wagner S, Allwardt D et al. Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity. Melanoma Res.15(2), 111–117 (2005).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Hantusch B, Sponer B et al. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol. Immunother.54(7), 677–684 (2005).
   PubMed Web of Science ®Google Scholar
• Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J. Immunol.174(11), 7104–7110 (2005).
   PubMed Web of Science ®Google Scholar
• Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J. Immunol.176(10), 6046–6054 (2006).
   PubMed Web of Science ®Google Scholar
• Hafner C, Samwald U, Wagner S et al. Selection of mimotopes of the cell surface adhesion molecule Mel-CAM from a random pVIII-28aa phage peptide library. J. Invest. Dermatol.119(4), 865–869 (2002).
   PubMed Web of Science ®Google Scholar
• Bramswig KH, Knittelfelder R, Gruber S et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin.Cancer Res.13(21), 6501–6508 (2007).
   PubMed Web of Science ®Google Scholar
• Park SH, Bae YM, Kwon HJ et al. JL1, a novel differentiation antigen of human cortical thymocyte. J. Exp. Med.178(4), 1447–1451 (1993).
   PubMed Web of Science ®Google Scholar
• Shin YK, Choi YL, Choi EY et al. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications. Cancer Immunol. Immunother.52(8), 506–512 (2003).
   PubMed Web of Science ®Google Scholar
• Chung J, Park S, Kim D et al. Identification of antigenic peptide recognized by the anti-JL1 leukemia-specific monoclonal antibody from combinatorial peptide phage display libraries. J. Cancer Res. Clin. Oncol.128(12), 641–649 (2002).
   PubMed Web of Science ®Google Scholar
• Xu L, Jin BQ, Fan DM. Selection and identification of mimic epitopes for gastric cancer-associated antigen MG7 Ag. Mol. Cancer Ther.2(3), 301–306 (2003).
   PubMed Web of Science ®Google Scholar
• Hang QL, Ding J, Gong AC et al. Screening of bioactive peptide that mimic the epitope of gastric cancer associated antigen. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi19(3), 308–310 (2003).
   PubMedGoogle Scholar
• Meng FP, Ding J, Yu ZC et al. Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J. Gastroenterol.11(12), 1833–1836 (2005).
   PubMed Web of Science ®Google Scholar
• Guo CC, Ding J, Pan BR et al. Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier. World J. Gastroenterol.9(6), 1191–1195 (2003).
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu K, Guo C et al. A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol. Ther.4(3), 308–312 (2005).
   PubMed Web of Science ®Google Scholar
• Shi R, Hong L, Wu D et al. Enhanced immune response to gastric cancer specific antigen peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion. Cancer Biol. Ther.4(2), 218–224 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang D, Chen Y, Fan D. MG7 mimotope-based DNA vaccination for gastric cancer. Expert Rev. Vaccines5(2), 223–231 (2006).
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst.94(11), 805–818 (2002).
   PubMed Web of Science ®Google Scholar
• El Kasmi KC, Deroo S, Theisen DM, Brons NH, Muller CP. Crossreactivity of mimotopes and peptide homologues of a sequential epitope with a monoclonal antibody does not predict crossreactive immunogenicity. Vaccine18(3–4), 284–290 (1999).
   PubMed Web of Science ®Google Scholar
• Weisser NE, Almquist KC, Hall JC. A rAb screening method for improving the probability of identifying peptide mimotopes of carbohydrate antigens. Vaccine25(23), 4611–4622 (2007).
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F. Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J. Immunol.179(11), 7967–7974 (2007).
   PubMed Web of Science ®Google Scholar
• Sette A, Livingston B, McKinney D et al. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals29(3–4), 271–276 (2001).
   PubMed Web of Science ®Google Scholar
• Desmezieres E, Jacob Y, Saron MF, Delpeyroux F, Tordo N, Perrin P. Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines. J. Gen.Virol.80(Pt 9), 2343–2351 (1999).
   PubMed Web of Science ®Google Scholar
• Astori M, Kraehenbuhl JP. Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic. Mol. Immunol.33(13), 1017–1024 (1996).
   PubMed Web of Science ®Google Scholar
• Dadaglio G, Moukrim Z, Lo-Man R, Sheshko V, Sebo P, Leclerc C. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis. Infect. Immun.68(7), 3867–3872 (2000).
   PubMed Web of Science ®Google Scholar
• Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumor escape. Semin. Cancer Biol.12(1), 25–31 (2002).
   PubMed Web of Science ®Google Scholar
• Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res.60(14), 3782–3789 (2000).
   PubMed Web of Science ®Google Scholar
• Walden P. Therapeutic vaccination for the treatment of malignant melanoma. Recent Results Cancer Res.176, 219–227 (2007).
   PubMedGoogle Scholar
• Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol. Immunother.55(8), 1025–1032 (2006).
   PubMed Web of Science ®Google Scholar